|Bid||55.50 x 1000|
|Ask||61.00 x 800|
|Day's range||56.84 - 58.06|
|52-week range||35.02 - 63.00|
|Beta (5Y monthly)||1.32|
|PE ratio (TTM)||N/A|
|Earnings date||26 Feb 2024 - 01 Mar 2024|
|Forward dividend & yield||N/A (N/A)|
|1y target est||71.87|
AUSTIN, Texas, December 06, 2023--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced new data being presented on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, at the 2023 San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas.
In the realm of stock market movements, insider trading activity is often a significant indicator that investors keep a close eye on.
AUSTIN, Texas, November 14, 2023--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it has entered into an agreement with Merck, known as MSD outside the United States and Canada, under which Merck will utilize Natera’s real-world database (RWD) to advance oncology research.